Phosphorylation of p21 in G 2/M promotes cyclin B-Cdc2 kinase activity

Molecular and Cellular Biology

Volumn 25, Issue 8, 2005, Pages 3364-3387

  Dash, Bipin C ^a   El Deiry, Wafik S ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; MUTANT PROTEIN; PROTEIN P21; APHIDICOLIN; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; NOCODAZOLE; PEPTIDE;

ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; WILD TYPE; ACTIVE TRANSPORT; CELL NUCLEUS; CHEMISTRY; GENETICS; METABOLISM; MITOSIS; MUTATION; NUCLEAR LOCALIZATION SIGNAL; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; APHIDICOLIN; CDC2 PROTEIN KINASE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL NUCLEUS; CYCLIN B; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ENZYME ACTIVATION; G2 PHASE; HUMANS; MITOSIS; MUTATION; NOCODAZOLE; NUCLEAR LOCALIZATION SIGNALS; PEPTIDES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 16244389645     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.25.8.3364-3387.2005     Document Type: Article

References (82)

1. Adams, P. D., W. R. Sellers, S. K. Sharma, A. D. Wu, C. M. Nalin, and W. G. Kaelin, Jr. 1996. Identification of a cyclin-Cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol. Cell. Biol. 16:6623-6633.
2. 1 cell cycle arrest in response to DNA damage. Cell 102:55-66.
3. 1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/Waf1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res. 57:1495-1501.
4. Asada, M., T. Yamada, H. Ichijo, D. Delia, K. Miyazono, and K. Fukumuro. 1999. Apoptosis inhibitory activity of cytoplasmic p21 Cip1/Waf1 in monocytic differentiation. EMBO J. 18:1223-1234.
5. Brugarolas, J., C. Chandrasekaran, J. I. Gordon, D. Beach, T. Jacks, and G. J. Hannon. 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377:552-557.
6. Bunz, F., A. A. Dutriaux, C. Lengauer, T. Waldman, S. Zhou, J. P. Brown, J. M. Sedivy. K. W. Kinzler, and B. Vogelstein. 1998. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497-1501.
7. Burns, T. F., P. Fei, K. A. Scata, D. T. Dicker, and W. S. El-Deiry. 2003. Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (Taxol)-exposed cells. Mol. Cell. Biol. 16:5556-5571.
8. Cayrol, C., and B. Ducommun. 1998. Interaction of cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21. Oncogene 17:2437-2444.
9. Chan, T. A., H. Hermeking, C. Lengauer, K. W. Kinzler, and B. Vogelstein. 1999. 14-3-3 sigma is required to prevent mitotic catastrophe after DNA damage. Nature 401:616-620.
10. Chan, T. A., P. M. Hwang, H. Hermeking, K. W. Kinzler, and B. Vogelstein. 2000. Cooperative effects of genes controlling the G2/M checkpoint. Genes Dev. 14:1584-1588.
11. Chen, J., P. K. Jackson, M. W. Kirschner, and A. Dutta. 1995. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 374:386-388.
12. Chen, J., R. Peters, R. Saha, P. Lee, A. Theodoras, M. Pagano, G. Wagner, and A. Dutta. 1996. A 39 amino acid fragment of the cell cycle regulator p21 is sufficient to bind PCNA and partially inhibit DNA replication in vivo. Nucleic Acids Res. 24:1727-1733.
13. Cheng, M., P. Olivier, J. A. Diehl, M. Fero, M. F. Roussel, J. M. Roberts, and C. J. Sherr. 1999. The p21 Cipl and p27 Kip1 CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 18:1571-1583.
14. 1 checkpoint control. Cell 82:675-684.
15. 2/M-phase transition. Mol. Cell. Biol. 18:546-557.
16. El-Deiry, W. S. 1998. p21/p53, cellular growth control and genomic integrity. Curr. Top. Microbiol. Immunol. 227:121-137.
17. El-Deiry, W. S. 2001. Akt takes centre stage in cell-cycle deregulation. Nat. Cell Biol. 3:E71-E73.
18. El-Deiry, W. S., T. Tokino, V. E. Velcutescu, D. B. Levy, R. Parsous, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. Waf1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
19. Erhardt, J. A., and R. N. Pittman. 1997. p21 Waf1 induces permanent growth arrest and enhances differentiation, but does not alter apoptosis in PC12 cells. Oncogene 16:443-451.
20. Fiol, C. J., A. M. Mahrenholz, Y. Wang, R. W. Roeske, and P. J. Roach. 1987. Formation of protein kinase recognition sites by covalent modification of the substrate. Molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3. J. Biol. Chem. 262:14042-14048.
21. Fisk, H. A., and M. Winey. 2001. The mouse Mpslp-like kinase regulates centrosome duplication. Cell 106:95-104.
22. Flores-Rozas, H., Z. Kelman, F. B. Dean, Z. Q. Pan, J. W. Harper, S. J. Elledge, M. O'Donnell, and J. Hurwitz. 1994. Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. Proc. Natl. Acad. Sci. USA 91:8655-8659.
23. Fotedar, R., P. Fitzgerald, T. Rousselle, D. Cannella, M. Doree, H. Messier, and A. Fotedar. 1996. p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity. Oncogene 12: 2155-2164.
24. Furstenthal, L., B. K. Kaiser, C. Swanson, and P. K. Jackson. 2001. Cyclin E uses Cdc6 as a chromatin-associated receptor required for DNA replication. J. Cell Biol. 152:1267-1278.
25. Glotzer, M., A. W. Murray, and M. W. Kirschner. 1991. Cyclin is degraded by the ubiquitin pathway. Nature 349:32-138.
26. Guadagno, T. M., and J. W. Newport. 1996. Cdk2 kinase is required for entry into mitosis as a positive regulator of Cdc2-cyclin B kinase activity. Cell 84:73-82.
27. Gulbis, J. M., Z. Kelman, J. Hurwitz, M. O'Donnell, and J. Kuriyan. 1996. Structure of the C-terminal region of p21 Waf1/Cip1 complexed with human PCNA. Cell 87:297-306.
28. Hall, C., D. M. Nelson, X. F. Ye, K. Baker, J. A. DeCaprio, S. Seeholzer, M. Lipinski, and P. D. Adams. 2001. HIRA, the human homologue of yeast Hir1p and Hir2p, is a novel cyclin-cdk2 substrate whose expression blocks S-phase progression. Mol. Cell. Biol. 21:1854-1865.
29. Hall-Jackson, C. A., D. A. E. Cross, N. Morrice, and C. Smythe. 1999. ATR is a caffeine-sensitive, DNA-activated protein kinase with a substrate specificity distinct from DNA-PK. Oncogene 18:6707-6713.
30. Harper, J. W., G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816.
31. Harper, J. W., S. J. Elledge, K. Keyomarsi, B. Dyndacht, L. H. Tsai, P. Zhang, S. Dobrowolski, C. Bai, L. Connell-Crowley, E. Swindell, M. P. Fox, and N. Wei. 1995. Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell. 6:387-400.
32. Hartley, R. S., R. E. Rempel, and J. L. Maller. 1996. In vivo regulation of the early embryonic cell cycle in Xenopus. Dev. Biol. 173:408-419.
33. Hengst, L., U. Gopfert, H. A. Lashuel, and S. I. Reed. 1998. Complete inhibition of Cdk/cyclin by one molecule of p21 cip1. Genes Dev. 12:3882-3888.
34. Hoffmann, I., G. Draetta, and E. Karsenti. 1994. Activation of the phosphatase activity of human cdc25A by a CDK2 cyclin-E dependent phosphorylation at the G(1)/S transition. EMBO J. 13:4302-4310.
35. Hu, B., J. Mitra, S. van den Heuvel, and G. H. Enders. 2001. S and G2 phase roles for Cdk2 revealed by inducible expression of a dominant-negative mutant in human cells. Mol. Cell. Biol. 21:2755-2766.
36. Izumi, T., and J. L. Maller. 1995. Phosphorylation and activation of the Xenopus cdc25 phosphatase in the absence of cdc2 and CDK2 kinase-activity. Mol. Biol. Cell 6:215-226.
37. Jaumot, M., J. M. Estanol, O. Casanovas, X. Grana, N. Agell, and O. Bachs. 1997. The cell cycle inhibitor p21(CIP) is phosphorylated by cyclin A-CDK2 complexes. Biochem. Biophys. Res. Commun. 241:434-438.
38. Jin, Z., D. T. Dicker, and W. S. El-Deiry. 2002. Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell cycle 1:82-89.
39. Kaneko, Y., N. Watanabe, H. Morisaki, H. Akita, A. Fujimoto, K. Tominaga, M. Terasawa, A. Tachibana, K. Ikeda, and M. Nakanishi. 1999. Cell cycle-dependent and ATM-independent expression of human Chk1 kinase. Oncogene 18:3673-3681.
40. King, R. W., R. J. Deshaies, J. M. Peters, and M. W. Kirschner. 1996. How proteolysis drives the cell cycle. Science 274:1652-1659.
41. Kriwacki, R. W., L. Hengst, L. Tennant, S. I. Reed, and P. E. Wright. 1996. Structural studies of p21Waf1/Cip1/Sdi1 in the free and Cdk2-bound state: conformational disorder mediates binding diversity. Proc. Natl. Acad. Sci. USA 93:11504-11509.
42. LaBaer, J., M. D. Garrett, L. F. Stevenson, J. M. Slingerland, C. Sandhu, H. S. Chou, A. Fattaey, and E. Harlow. 1997. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11:847-862.
43. Li, R., S. Waga, G. J. Hannon, D. Beach, and B. Stillman. 1994. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 371:534-537.
44. Li, R., G. J. Hannon, D. Beach, and B. Stillman. 1996. Subcellular distribution of p21 and PCNA in normal and repair-deficient cells following DNA damage. Curr. Biol. 6:189-199.
45. Li, Y., C. W. Jenkins, M. A. Nichols, and Y. Xiong. 1994. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 9:2261-2268.
46. Luo, Y., J. Hurwitz, and J. Massague. 1995. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21 cipl. Nature 375:159-161.
47. Macleod, K. F., N. Sherry, G. Hannon, D. Beach, T. Tokino, K. Kinzler, B. Vogelstein, and T. Jacks. 1995. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 9:935-944.
48. Morgan, D. O. 1995. Principles of CDK regulation. Nature 374:131-134.
49. Morgan, D. O. 1997. Cyclin dependent kinases; engines, clocks, and microprocessors. Annu. Rev. Cell Dev. Biol. 13:261-291.
50. Morgan, D. O. 1999. Regulation of the APC and the exit from mitosis. Nat. Cell Biol. 2:E47-E53.
51. Nigg, E. A. 2001. Mitotic kinases as regulators of cell division and its checkpoints. Nat. Rev. Mol. Cell Biol. 2:21-32.
52. O'Conner, P. M., D. K. Ferris, M. Pagano, G. Draetta, J. Pines, T. Hunter, D. L. Longo, and K. W. Kohn. 1993. G2 delay induced by nitrogen mustard in human cells affects cyclin A/xsk2 and cyclin B1/cdc2-kinase complexes differently. J. Biol. Chem. 268:8298-8308.
53. Pandita, T. K., H. B. Lieberman, D.-S. Lim, S. Dhar, W. Zheng, Y. Taya, and M. B. Kastan. 2000. Ionizing radiation activates the ATM kinase throughout the cell cycle. Oncogene 19:1386-1391.
54. Parker, S. B., G. Eichele, P. Zhang, A. Rawls, A. T. Sands, A. Bradley, E. N. Olson, J. W. Harper, and S. J. Elledge. 1995. p53-independent expression of p21 Cip1 in mouse and other terminally differentiated cells. Science 267: 1024-1027.
55. Pines, J. 1999. Four-dimensional control of the cell cycle. Nat. Cell Biol. 1:E73-E79.
56. Roberts, J. M. 1999. Evolving ideas about cyclins. Cell 98:129-132.
57. Rosenblatt, J., Y. Gu, and D. O. Morgan,. 1992. Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A. Proc. Natl. Acad. Sci. USA 89:2824-2828.
58. CiP1 degradation. J. Biol. Chem. 277:9684-9689.
59. Sarcevic, B., A. Mawson, R. T. Baker, and R. L. Sutherland. 2002. Regulation of the ubiquitin-conjugating enzyme hHR6A by CDK-mediated phosphorylation. EMBO J. 21:2009-2018.
60. Sarkaria, J. N., S. T. Randal, E. C. Busby, A. P. Kennedy, D. E. Hill, and R. T. Abraham. 1998. Inhibition of phosphoinositides 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res. 58:4375-4382.
61. Schulman, B. A., D. L. Lindstrom, and E. Harlow. 1998. Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A. Proc. Natl. Acad. Sci. USA 95:10453-10458.
62. Scott, M. T., N. Morrice, and K. L. Ball. 2000. Reversible phosphorylation at the C-terminal regulatory domain of p21 waf1/Cip1 modulates proliferating cell nuclear antigen binding. J. Biol. Chem. 275:11529-11537.
63. Sherr, C. J. 1993. Mammalians G1 cyclins. Cell 73:1059-1065.
64. Sherr, C. J. 1994. G1 phase progression: cycling on cue. Cell 79:551-555.
65. Sherr, C. J., and J. M. Roberts. 1999. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1501-1512.
66. Spruck, C. H., K.-A. Won, and S. I. Reed. 1999. Deregulated cyclin E induces chromosome instability. Nature 401:297-300.
67. Stewart, Z. A., S. D. Leach, and J. A. Pietenpol. 1999. p21 (Waf1/Cip1) inhibition of cyclin E/Cdk2 activity prevents endoreduplication after mitotic spindle disruption. Mol. Cell. Biol. 19:205-215.
68. Toyoshima-Morimoto, F., E. Taniguchi, N. Shinya, A. Iwamatsu, and E. Nishida. 2001. Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature 410:215-220.
69. Waga, S., G. J. Hannon, D. Beach, and B. Stillman. 1994. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369:574-578.
70. Waga, S., and B. Stillman. 1998. Cyclin-dependent kinase inhibitor p21 modulates the DNA primer-template recognition complex. Mol. Cell. Biol. 18:4177-4187.
71. Waldmann, T., C. Lengauer, K. Kinzler, and B. Vogelstein. 1996. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381:713-716.
72. Warbrick, E. 1998. PCNA binding through a conserved motif. BioEssays 20:195-199.
73. Warbrick, E., D. P. Lane, D. M. Glover, and L. S. Cox. 1995. A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21 waf1 and proliferating cell nuclear antigen. Curr. Biol. 5:275-282.
74. Wei, Y., H. P. Jin, and J. W. Harper. 2003. The cyclin E/Cdk2 substrate and Cajal body component p220 (NPAT) activates histone transcription through a novel LisH-Like domain. Mol. Cell. Biol. 23:3669-3680.
75. Xiong, Y., G. J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach. 1993. p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704.
76. Xiong, Y., H. Zhang, and D. Beach. 1992. D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71:505-514.
77. Ye, X., Y. Wei, G. Nalepa, and J. W. Harper. 2003. The cyclin E/Cdk2 substrate p220 (NPAT) is required for S-phase entry, histone gene expression, and Cajal body maintenance in human somatic cells. Mol. Cell. Biol. 23:8586-8600.
78. Zhang, H., Y. Xiong, and D. Beach. 1993. Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol. Biol. Cell. 4:897-906.
79. Zhang, H., G. J. Hannon, and D. Beach. 1994. p21-containing cyclin kinases exists in both active and inactive states. Genes Dev. 8:1750-1758.
80. Zhang, H., G. J. Hannon, D. Casso, and D. Beach. 1994. p21 is a component of active cell cycle kinases. Cold Spring Harbor Symp. Quant. Biol. 59:21-29.
81. Zhou, B.-B. S., P. Chaturvedi, K. Spring, K., S. P. Scott, R. A. Johnson, R. Mishra, M. R. Mattern, J. D. Winkler, and K. K. Khanna. 2000. Caffeine abolishes the mammalian G2/M DNA damage checkpoint by inhibiting ataxia-telangiectasia-mutated kinase activity. J. Biol. Chem. 275:10342-10348.
82. Zhou, B. P., Y. Liao, W. Xia, B. Spohn, M.-H. Lee, and M. C. Hung. 2001. Cytoplasmic localization of p21 Cip1/Waf1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell Biol. 3:245-251.